Vor Biopharma Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Vor Biopharma Inc. (VOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $11.65 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-11
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $11.75, a 40.66% decline year-over-year.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $19.80, a 976.09% increase year-over-year.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.84, a 53.77% decline year-over-year.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $3.98, a 31.85% decline year-over-year.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $15.09, a 49.02% decline from fiscal 2024.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $29.60, a 731.46% increase from fiscal 2023.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.56, a 49.86% decline from fiscal 2022.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $7.10, a 45.97% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.65 10-Q · filed 2026-08-11 | |||||||
| 2026-03-31 | $11.75 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | $15.09 10-K · filed 2026-03-30 | |||||||
| 2025-09-30 | $17.30 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | $14.60 10-Q · filed 2026-08-11 | $0.73 10-Q · filed 2025-08-12 | ||||||
| 2025-03-31 | $19.80 10-Q · filed 2026-05-13 | $0.99 10-Q · filed 2025-05-14 | ||||||
| 2024-12-31 | $29.60 10-K · filed 2026-03-30 | $1.48 10-K · filed 2025-03-20 | ||||||
| 2024-09-30 | $29.80 10-Q · filed 2025-11-13 | $1.49 10-Q · filed 2024-11-07 | ||||||
| 2024-06-30 | $1.74 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | $1.84 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | $3.56 10-K · filed 2025-03-20 | |||||||
| 2023-09-30 | $3.65 10-Q · filed 2024-11-07 | |||||||
| 2023-06-30 | $3.76 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | $3.98 10-Q · filed 2024-05-09 | $5.53 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | $7.10 10-K · filed 2024-03-20 | |||||||
| 2022-09-30 | $5.08 10-Q · filed 2023-11-07 | $7.47 10-Q · filed 2022-11-10 | ||||||
| 2022-06-30 | $5.65 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $5.84 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | $13.14 10-K · filed 2023-03-23 | |||||||
| 2021-09-30 | $13.71 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | $15.40 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | $15.27 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $2.19 10-K · filed 2022-03-14 | |||||||
| 2020-03-31 | $1.42 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |